Evidence map›Paper›PMID 35013800›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2022

Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration.

Joel Hanhart, Rony Wiener, Hashem Totah, Evgeny Gelman, Yishay Weill, Adi Abulafia, David Zadok

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joel HanhartDepartment of Ophthalmology, Shaare Zedek Medical Center, Affiliated to the Hebrew University, 12 Shmuel Bait St., 9103102, Jerusalem, Israel. hanhart@szmc.org.il.ORCID http://orcid.org/0000-0003-0952-3740
Rony WienerDepartment of Ophthalmology, Shaare Zedek Medical Center, Affiliated to the Hebrew University, 12 Shmuel Bait St., 9103102, Jerusalem, Israel.
Hashem TotahDepartment of Ophthalmology, Shaare Zedek Medical Center, Affiliated to the Hebrew University, 12 Shmuel Bait St., 9103102, Jerusalem, Israel.
Evgeny GelmanDepartment of Ophthalmology, Shaare Zedek Medical Center, Affiliated to the Hebrew University, 12 Shmuel Bait St., 9103102, Jerusalem, Israel.
Yishay WeillDepartment of Ophthalmology, Shaare Zedek Medical Center, Affiliated to the Hebrew University, 12 Shmuel Bait St., 9103102, Jerusalem, Israel.
Adi AbulafiaDepartment of Ophthalmology, Shaare Zedek Medical Center, Affiliated to the Hebrew University, 12 Shmuel Bait St., 9103102, Jerusalem, Israel.
David ZadokDepartment of Ophthalmology, Shaare Zedek Medical Center, Affiliated to the Hebrew University, 12 Shmuel Bait St., 9103102, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the impact of COVID-19-related delay in intravitreal injection timing on macular structure and visual acuity (VA) among patients treated for neovascular age-related macular degeneration (nvAMD).

methodsWe reviewed demographic and clinical data and macular ocular computerized tomographic images of 34 patients (48 eyes, group A) who did not follow their injection schedule during the first wave of COVID-19 and compared them to 46 patients (71 eyes, group B) who did. Functional worsening was defined as a loss of at least 0.1 in decimal VA. Anatomic worsening was defined as new or increased subretinal/intraretinal fluids or new hemorrhage.

resultsThe planned mean ± standard deviation intervals between the intravitreal injections were 5.7 ± 2.7 weeks for group A and 5.5 ± 2.4 weeks for group B (P = 0.60). The actual intervals were 13.6 ± 6.8 (7.9 ± 5.2 weeks' delay) and 5.3 ± 2.4 weeks (no delay), respectively (P < 0.001). The best corrected visual acuity worsened in 23 group A eyes (47.9%) and in 6 group B eyes (8.5%) (odds ratio [OR] 9.97, P < 0.001). Anatomic features indicative of nvAMD worsening were detected in 31 group A eyes (64.6%) and in 16 group B eyes (22.5%) (OR 5.73, P < 0.001). A new macular hemorrhage was observed in 4 group A eyes (8.3%) and in no group B eyes (P = 0.09).

conclusionDelay in timely retinal care during the COVID-19 restrictions period resulted in short-term negative outcomes, including macular bleeding, in nvAMD patients.

Indexed as

COVID-19Macular DegenerationWet Macular DegenerationAngiogenesis InhibitorsFollow-Up StudiesHumansIntravitreal InjectionsRanibizumabTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsAMDAnti-VEGFCOVID-19DelayDisruptionOCT

Identifiers

PMID35013800
PMCPMC8747863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.